Abstract: Chemotherapy is one of the most effective forms of cancer treatment. It has been widely used in the treatment of various malignant tumours. To investigate molecular mechanisms responsible for the chemoresistance of anaplastic thyroid cancer (ATC), we established the doxorubicin (Dox) resistance of human ATC SW1736 and 8305C cells and named them SW1736/Dox and 8305C/Dox, respectively. We evaluated the expression of various micro-RNAs (miRNAs) between control and Dox-resistant ATC cells and found that the expression of miR-27b-3p was significantly increased in Dox-resistant ATC cells. Targeted inhibition of miR-27b can increase the sensitivity of SW1736/Dox and 8305C/Dox cells. Bioinformatics analysis revealed that miR-27b can directly target peroxisome proliferator-activated receptor gamma (PPARc) within the 3 0 untranslated region (UTR). This was proved by the results that miR-27b-3p down-regulated the protein and mRNA levels of PPARc. While the mutant in the core binding sites of PPARc abolished miR-27b-3p-induced down-regulation of luciferase activity. Over-expression of PPARc can increase the Dox sensitivity of SW1736/Dox and 8305C/Dox cells. Basic fibroblast growth factor (bFGF) might be involved in miR-27b-3p/PPARc-regulated Dox resistance of ATC cells. The activation of p65 nuclear factor-jB (NF-jB) regulated the up-regulation of miR-27b-3p in Dox-resistant ATC cells. Collectively, our data revealed that miR-27b-3p/PPARc is involved in the Dox resistance of human ATC cells. It suggested that targeted inhibition of miR-27b-3p might be helpful to overcome the drug resistance of ATC cells.
Thyroid carcinoma is the most common endocrine malignancy with increasing incidence worldwide. It is the fifth most prevalent cancer in women, with over 62,000 new cases estimated for 2015 [1] . Although anaplastic thyroid carcinoma (ATC) only makes up about 2% of all the cases of thyroid cancer [2] , the fast proliferation and rapid increase in size leads it to account for more than 50% of thyroid cancer mortality [3] . It is highly resistant to most of therapy approaches including radiotherapy and/or chemotherapy [4] . These therapies sometimes fail due to therapeutic resistance. For example, resistance to chemotherapy occurs in most patients with ATC [5] . Although these tumours have a relatively low frequency, there is an urgent need for investigation of mechanisms responsible for drug resistance of ATC cells. Doxorubicin (Dox) is one of the most widely used drugs to treat cancers by suppressing DNA polymerase, DNA topoisomerase II and DNA methyltransferase [6] . Dox as a single treatment, without radiotherapy, is reserved only for ATC patients with unresectable or metastatic disease, while in all other cases of ATC, a combination of docetaxel + Dox, with or without radiotherapy, is the treatment of choice [7] . However, the response rate for Dox treatment is poor due to the development of chemoresistance [8] , which might be due to the up-regulation of multidrug-resistant proteins and activation of prosurvival pathways [9, 10] . Further investigations of the mechanisms for Dox resistance of ATC cells will be of great help for its clinical application.
Micro-RNAs (miRNAs) have been suggested to be involved in the progression of ATC. As a non-coding RNA of approximately 22 nucleotides in length, it can regulate the expression of mRNAs following their binding to the 3 0 untranslated region (UTR) [11] . The binding between miRNA and mRNA will inhibit the translation or lead to mRNA degradation [12] . In ATC, significant decrease in miR-30d, miR-125b, miR-26a and miR-30a-5p was detected [13] . miRNA has been suggested to be involved in proliferation or apoptosis in ATC cells [14] , while its roles in chemoresistance are not well illustrated. Our present study established the Dox-resistant human ATC SW1736 and 8305C cells. We found that miR-27b-3p/ peroxisome proliferator-activated receptor gamma (PPARc) is involved in the Dox resistance of human ATC cells. real-timepolymerase chain reaction (PCR) Kit (Takara, Shiga, Japan). Realtime PCR was conducted by use of SYBR Premix EX Taq (Takara) on Rotor-gene Q Instrument (Qiagen, Milan, Italy). Reactions were carried out at 95°C for 30 sec. as an initial activation, followed by 40 cycles at 95°C for 5 sec. and 60°C for 30 sec. GAPDH was used as the loading control for normalization of miRNA and messenger RNA (mRNA), respectively. The primer sequences were used as follows: P-pg (ABCB1) forward: 5 0 -GCT GTC AAG GAA GCC AAT GCC T- For real-time PCR analysis of miRNAs, the RNA was extracted by the use of mirVana miRNA Isolation kit (Ambion, Austin, TX, USA). The cDNA was synthesized by use of Taqman MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). The qRT-PCR was performed by use of Taqman Universal PCR Master Mix (Applied Biosystems) with the provided universal primer and mature miRNA-specific primers. U6 was used as miRNA reference gene.
Materials and Methods
Western blot analysis. Cells were lysed by use of M-PER mammalian protein extraction reagent (Pierce Biotechnology, Rockford, IL, USA). The mixture was centrifuged at 12,000 9 g for 10 min., and the supernatant was collected. The protein concentration was measured and equal amounts (10-20 lg) of proteins were resolved by SDSpolyacrylamide gel electrophoresis (SDS-PAGE). The proteins were transferred to PVDF membranes (Bio-Rad, Hercules, CA, USA) and blocked with 5% bovine serum albumin (BSA, w/v) at room temperature for 1 hr. Then, the membrane was incubated with the primary antibody at 4°C overnight. After washing three times with PBS, it was further incubated with an appropriate secondary antibody coupled to horseradish peroxidase at room temperature for 1 hr. The protein was visualized by chemiluminescence ECL reagent (LumiGold, SignaGen Laboratories, Rockville, MD, USA) and detected by a CCD camera (Bio-Rad Laboratories, Hercules, California, USA). GAPDH was used as the loading internal control. To analyse the expression of p65 in nuclear, the sub-cellular fraction was extracted by the use of NE-PER fractionation kit (Pierce, Rockford, IL, USA) according to the instructions of the manufacturer.
Dual-luciferase reporter assay. To evaluate the potential roles of miRNA on the target mRNA, the 3 0 -UTR containing miR-27b targeting sequence was inserted into the pGL3 basic plasmid and analysed with the Dual-Luciferase Reporter Assay system (Promega, WI, USA) according to the instructions of manufacturer. Briefly, cells at 70% confluence were co-transfected with either pGL3-WT-TRIM8-3 0 -UTR (wild-type) or pGL3-Mut-TRIM8-3 0 -UTR (mutant) vector caring the miR-182 mimic for 48 hr. The firefly luciferase activity was normalized to the Renilla luciferase activity.
Enzyme-linked immunosorbent assay. The concentrations of bFGF in medium were measured by Enzyme-linked immunosorbent assay (ELISA) kit (Human bFGF ELISA; RayBio Inc., Norcross, Canada) according to the instructions of manufacturer.
Statistical analysis. All data were evaluated by the use of SPSS (IBM Inc, Armonk, NY, USA). Two groups were compared with Student's t-test. p < 0.05 was considered statistically significant.
Results
The establishment of Dox-resistant ATC cells. We generated the Dox-resistant cells via culturing human ATC cells SW1736 and 8305C with increasing concentration of Dox. At the end of the experiment, we examined the effects of Dox on the proliferation of parent and Dox-resistant ATC cells. Our data showed that both SW1736 ( fig. 1A ) and 8305C ( fig. 1B) were significantly more sensitive to Dox than SW1736/Dox and 8305C/Dox, respectively. The IC 50 value of Dox to SW1736/Dox (8.8 lM) was about 11 times higher than that of parent SW1736 (0.82 lM). The IC 50 value of Dox to 8305C/Dox (9.2 lM) was about 5.4 times higher than that of parent 8305C (1.7 lM). Furthermore, both qRT-PCR ( fig. 1C ) and western blot analysis ( fig. 1D) showed that the expression of P-gp (encoded by ABCB1) was significantly increased in Dox-resistant ATC cells.
miR-27b is up-regulated in Dox-resistant ATC cells. It was reported that miRNAs such as miR-200a/b/c, miR-141, miR-205 and miR-27b are involved in the Dox resistance of cancer cells [15] . We therefore evaluated the expression of PPARG is a target of miR-27b-3p in ATC cells. To find the potential targets for miR-27b function in ATC Dox-resistant cells, we used TargetScan4.0 and miRanda to predict targets of miR-27b in human species. The genes involved in cell proliferation and Dox resistance were used for further analysis. We found PPARG gene that encoded the PPARc as a potential target for miR-27b with the target site locating at nucleotides 82 and 88 within the 3 0 UTR (fig. 3A) .
We then evaluated the effects of miR-27b-3p on the expression of mRNA and protein of PPARc. We found that miR27b-3p mimic can significantly down-regulate the mRNA expression of PPARG in both SW1736 and 8305C cells ( fig. 3B ). It was confirmed that miR-27b-3p can also inhibit the protein expression of PPARc in both SW1736 and 8305C cells ( fig. 3C ). To confirm that PPARG is a direct target of miR-27b-3p, we constructed pGL3-PPARG-3 0 UTR and pGL3-PPARG-3 0 UTR-mut (mutant the binding site ACUGUGA to AGAGACU). The dual-luciferase reporter assay showed that miR-27b-3p can cause a 45% decrease in the luciferase activity compared with the negative control; however, this suppression was reversed by the five-nucleotide substitution in the core binding sites ( fig. 3D ). This result confirmed that mRNA of PPARG is a direct target of miR-27b-3p in ATC cells.
PPARc is involved in miR-27b-3p-regulated Dox resistance of ATC cells. expression of PPARc between parental and Dox-resistant cells. Our data showed that mRNA expression of PPARc in SW1736 and 8305C cells was significantly lower than that in the SW1736/Dox and 8305C/Dox cells, respectively ( fig. 4A ). This was confirmed by western blot analysis ( fig. 4B ). To investigate whether PPARc was involved in miR-27b-3p-regulated Dox resistance, we over-expressed PPARc in cells by transfection of pcDNA/PPARc plasmid ( fig. 4C) . The results confirmed that over-expression of PPARc increased the Dox sensitivity of both SW1736/Dox ( fig. 4D ) and 8305C/Dox ( fig. 4E ) cells. These data suggest that PPARc is involved in miR-27b-3p-regulated Dox resistance of ATC cells.
bFGF might be involved in miR-27b-3p/PPARc-regulated Dox resistance of ATC cells. Previous studies have suggested that c-Myc, Bcl2, bFGF and VEGF are the targets of PPARc during cancer cell proliferation [16] . We tested the effects of miR-27b-3p on the mRNA expression of these downstream molecules in ATC cells. The results showed that miR-27b-3p significantly decreased the expression of bFGF in both SW1736 ( fig. 5A ) and 8305C ( fig. 5B ) cells. ELISA confirmed that miR-27b-3p decreased the expression of bFGF in both SW1736 and 8305C cells ( fig. 5C ). Consistently, decreased expression of bFGF was also observed in both SW1736/Dox and 8305C/Dox cells as compared with their control cells ( fig. 5D ). Bioinformatics analysis did not find the binding site between miR-27b-3p and the 3 0 UTR of bFGF mRNA. Over-expression of PPARc can reverse miR-27b-3p-induced down-regulation of bFGF expression in both SW1736 ( fig. 5E ) and 8305C ( fig. 5F ) cells.
Considering the positive roles of bFGF on cell proliferation, our data suggest that bFGF might be involved in miR-27b-3p/ PPARc-regulated Dox resistance of ATC cells.
p65 NF-jB is involved in the up-regulation of miR-27b-3p in ATC Dox-resistant cells.
We therefore investigated the mechanisms responsible for the up-regulation of miR-27b-3p in ATC Dox-resistant cells. Several reports have shown that NF-jB is an indispensable mechanism in the regulation of miR-27b [17, 18] . We checked the expression of p65 in ATC and Dox-resistant cells. Western blot analysis showed that the total ( fig. 6A ) and nuclear ( fig. 6B ) levels of p65 in SW1736/Dox and 8305C/Dox cells were significantly higher than in corresponding controls. Furthermore, BAY-11-7082 (BAY), the inhibitor of p65 NF-jB, can significantly inhibit the expression of miR-27b-3p ( fig. 6C ), while it up-regulates PPARc ( fig. 6D ) in both SW1736/Dox and 8305C/Dox cells. Collectively, the results suggest that p65 NF-jB is involved in the up-regulation of miR-27b-3p in ATC Dox-resistant cells. Dox-resistant cells. Bioinformatics analysis and dual-luciferase reporter assay showed that PPARc is a direct target of miR-27b-3p, while over-expression of PPARc also increased the Dox sensitivity of ATC-resistant cells. bFGF, the downstream of PPARc, might be involved in miR-27b-3p/PPARc-regulated Dox resistance of ATC cells. Finally, up-regulation of p65 NFjB is involved in the up-regulation of miR-27b-3p in ATC Dox-resistant cells. Collectively, our study reveals that p65 NFΚb-induced up-regulation of miR-27b-3p can mediate the Dox resistance of ATC cells via targeting inhibition of PPARc. miR-27b-3p can regulate the progression of cancer via modulation of cell growth, invasion and metastasis [20, 21] . Increased expression of miR-27b-3p has been observed in breast [22] and glioma [23] cancer cells. Over-expression of miR-27b-3p can trigger the proliferation and suppress the apoptosis of cervical cancer cells by targeting polo-like kinase 2 [24] . Consistently, knockdown of miR-27b-3p can induce cell proliferation and anchorage-independent growth of breast cancer cells [22] . Our data also showed that miR-27b-3p increased the Dox resistance in cells, while targeted inhibition of miR-27b-3p can increase the sensitivity of Dox. However, some reports also suggested that miR-27b is crucial for proliferation inhibition in multiple tumours. For example, miR-27b-3p can inhibit the proliferation of gastric cells via targeting Frizzled7 (FZD7) [25] . It is suggested that the oncogenic roles of miR-27b-3p might be cancer-dependent.
Our data showed that PPARc is involved in miR-27b-3p-maintained Dox resistance of ATC cells. A previous study suggested that miR-27b can target many genes in human cells including EGFR, c-Met, AT14, PLK2, CCNGI and PPARc [18] . Our present study, together with previously published results [26, 27] , confirmed that miR-27b-3p can target the PPARc 3 0 UTR in various human cell lines. PPARc belongs to the nuclear receptor superfamily and acts as a tumour suppressor in various types of cancer [28] . It was reported that activation of PPARc can suppress the proliferation and invasion in glioblastoma [29] and induce apoptosis in non-smallcell lung cancer cells [30] . Our present study showed that over-expression of PPARc can attenuate Dox resistance of SW1736/Dox and 8305C/Dox cells, suggesting that miR-27b-3p-regulated PPARc expression is involved in Dox resistance of ATC cells. Our present study also showed that bFGF and p65 NF-jB are the down-and upstream signals for miR-27b-3p/PPARc axis in ATC cells. Our data showed that PPARc can positively regulate the expression of bFGF in ATC cells, which is in consistency with the recently published data revealing that PPARc ligands inhibit bFGF-mediated angiogenesis in chick chorioallantoic membrane (CAM) model [31] . Another study also showed that bFGF can protect cells from Dox-induced damage on efflux transporters [32] . Here, we demonstrated that NF-jB can regulate expression of miR-27b in ATC cells, which corresponds to results that uncovered Her2/neu(ERBB2) increases miR-27b expression through the PI3K/AKT/NF-jB signalling cascade [22] . In biliary epithelial cells, it was also reported that NF-jB p65 can transactivate miR-27b cluster genes [33] . The hypermethylation in the miR-27b gene promoter region can suppress its expression in colon cancer cells [34] . Whether promoter methylation can regulate the expression of miR-27b-3p in ATC cells needs further study.
Taken together, our present study revealed that miR-27b-3p/ PPARc is involved in Dox resistance of ATC cells. bFGF and p65 NF-jB are the down-and upstream signals for miR-27b-3p/PPARc axis and also involved in Dox resistance. Our study suggested that miR-27b-3p might be a potential target for overcoming ATC resistance to Dox.
